↓ Skip to main content

Moringa oleifera Seed Extract Alleviates Scopolamine-Induced Learning and Memory Impairment in Mice

Overview of attention for article published in Frontiers in Pharmacology, April 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
1 news outlet
twitter
1 X user

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
89 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Moringa oleifera Seed Extract Alleviates Scopolamine-Induced Learning and Memory Impairment in Mice
Published in
Frontiers in Pharmacology, April 2018
DOI 10.3389/fphar.2018.00389
Pubmed ID
Authors

Juan Zhou, Wu-shuang Yang, Da-qin Suo, Ying Li, Lu Peng, Lan-xi Xu, Kai-yue Zeng, Tong Ren, Ying Wang, Yu Zhou, Yun Zhao, Li-chao Yang, Xin Jin

Abstract

The extract of Moringa oleifera seeds has been shown to possess various pharmacological properties. In the present study, we assessed the neuropharmacological effects of 70% ethanolic M. oleifera seed extract (MSE) on cognitive impairment caused by scopolamine injection in mice using the passive avoidance and Morris water maze (MWM) tests. MSE (250 or 500 mg/kg) was administered to mice by oral gavage for 7 or 14 days, and cognitive impairment was induced by intraperitoneal injection of scopolamine (4 mg/kg) for 1 or 6 days. Mice that received scopolamine alone showed impaired learning and memory retention and considerably decreased cholinergic system reactivity and neurogenesis in the hippocampus. MSE pretreatment significantly ameliorated scopolamine-induced cognitive impairment and enhanced cholinergic system reactivity and neurogenesis in the hippocampus. Additionally, the protein expressions of phosphorylated Akt, ERK1/2, and CREB in the hippocampus were significantly decreased by scopolamine, but these decreases were reversed by MSE treatment. These results suggest that MSE-induced ameliorative cognitive effects are mediated by enhancement of the cholinergic neurotransmission system and neurogenesis via activation of the Akt, ERK1/2, and CREB signaling pathways. These findings suggest that MSE could be a potent neuropharmacological drug against amnesia, and its mechanism might be modulation of cholinergic activity via the Akt, ERK1/2, and CREB signaling pathways.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 89 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 11%
Student > Bachelor 10 11%
Lecturer 4 4%
Researcher 4 4%
Other 3 3%
Other 11 12%
Unknown 47 53%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 9 10%
Medicine and Dentistry 7 8%
Biochemistry, Genetics and Molecular Biology 6 7%
Agricultural and Biological Sciences 6 7%
Neuroscience 6 7%
Other 7 8%
Unknown 48 54%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2018.
All research outputs
#3,238,575
of 23,047,237 outputs
Outputs from Frontiers in Pharmacology
#1,433
of 16,374 outputs
Outputs of similar age
#67,959
of 326,487 outputs
Outputs of similar age from Frontiers in Pharmacology
#50
of 395 outputs
Altmetric has tracked 23,047,237 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,374 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,487 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 395 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.